stock rating
Hologic Upgraded to Outperform by Evercore ISI
Investors are refocusing on Hologic's base business given an anticipated major cut to COVID-19 industry testing revenues in fiscal year 2022, according to Evercore.
Piper Sandler Raises Rating on Oncocyte to Overweight
The rating increase follows Oncocyte's Chinese distribution deal for its DetermaRx lung cancer treatment stratification test with Burning Rock Biotech.
JP Morgan Downgrades Illumina to Neutral on Grail Deal
Along with the downgrade, the investment bank also lowered its December 2021 price target for Illumina from $390 to $280.
Oppenheimer Initiates Coverage of Fulgent Genetics With Outperform Rating
The investment banking firm forecast Fiscal Year 2021 revenues of $235.6 million, higher than the consensus Wall Street estimate of $178.4 million.
BTIG, Canaccord Genuity Initiate Coverage of Genetron with Buy Ratings
BTIG put a $20 target price on Genetron's shares, while Canaccord Genuity is targeting $19 per share for the Chinese genomics and cancer diagnostics firm.
Oct 14, 2019
William Blair, Cowen Initiate Coverage of Exagen
Jun 11, 2019
Piper Jaffray Initiates Coverage of Danaher, Agilent
Jun 1, 2018
Leerink Upgrades T2 Biosystems to To Outperform
May 24, 2018
Vermillion Downgraded by Canaccord to Hold Rating
Feb 15, 2018
Foundation Medicine Coverage Initiated by Cowen
Dec 13, 2017